TPIV200 stimulates T cells to attack ovarian and triple-negative breast tumor cells that over-express the folate receptor alpha protein.
A Moffitt team suggests mathematical modeling may guide the optimal cancer treatment dosing approach better than MTD.
Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors.
In this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS’s role in developing an ASCO/NCCN guideline for their management.
A streamlined nursing protocol reduced delays related to treatment with oral formulations of chemotherapy and immunotherapy, and increased patient satisfaction.
An intravesical instillation of gemcitabine following TURBT reduced the risk of recurrence in patients with suspected low-grade non–muscle-invasive urothelial cancer.
A retrospective study shows 30 patients need to be treated with adjuvant therapy to prevent 1 death at 3 years.
The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.
Researchers from MD Anderson say their study results "open the field of immunoprevention in LS to checkpoint inhibitors as an immune interception strategy."
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy.